cyb003
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Jul 6, 2022 (NCT05385783)
Timeline
Indications
Mechanism of action
HTR2A agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06793397 | Phase 3 | Jul 8, 2025 | Cybin Therapeutics Inc., Worldwide Clinical Trials |
| NCT06820723 | Phase 2 | Mar 31, 2025 | Ohio State University |
| NCT06605105 | Phase 3 | Feb 23, 2025 | Cybin Therapeutics Inc., Worldwide Clinical Trials |
| NCT06564818 | Phase 3 | Nov 30, 2024 | Cybin Therapeutics Inc., Worldwide Clinical Trials |
| NCT05385783 | Phase 1/Phase 2 (Phase 2) | Jul 6, 2022 | Clinilabs, Cybin Therapeutics Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cybin Therapeutics Inc. | For profit | 4 | 4 | 2 | 2022 |
| Worldwide Clinical Trials | For profit | 3 | 0 | 1 | 2024 |
| Clinilabs | For profit | 1 | 0 | 1 | 2022 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1